Tarsus Pharmaceuticals, Inc. TARS Sales-based Milestones — Maximum milestone payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept tars:CollaborativeArrangementMaximumMilestonePayment.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
The Company made cash payments under the All Human Uses Elanco Agreement of $0.5 million related to a clinical milestone that was triggered in December 2022 upon enrollment of the first patient in the Phase 2a Carpo trial, for the potential treatment of Lyme disease. The Company is required to make potential future cash payments under this agreement upon the achievement of various clinical milestones up to an aggregate maximum of $4.0 million and various commercial and sales threshold milestones for an aggregate maximum of $77.0 million. In addition, the Company will be obligated to pay contractual royalties in the single digits of its product sales, net. If the Company receives certain types of payments from its sublicensees, it will also be obligated to pay a variable percentage in the low to mid double-digits of such proceeds, until achievement of the first applicable regulatory approval of a product covered under the license.
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s sales-based milestones — maximum milestone payments?
- Tarsus Pharmaceuticals, Inc. (TARS) reported sales-based milestones — maximum milestone payments of $4M in Q2 2026.
- What does sales-based milestones — maximum milestone payments mean?
- This metric represents the total potential future cash payments contingent upon achieving specific commercial sales thresholds for a licensed or acquired pharmaceutical product. It quantifies the maximum financial obligation or upside associated with the successful market penetration and revenue growth of a therapeutic asset. Investors use this to assess the long-term commercial risk and the potential cost structure tied to the successful commercialization of a drug candidate.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s sales-based milestones — maximum milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
